NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Nektar Therapeutics (NKTR) Stock Analysis

Nektar Therapeutics (NKTR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NKTR

$38.27

−$0.95 (−2.42%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NKTR with… →

NKTR Key Statistics

As of Oct 21, 2026
Trading
Open
$39.09
Previous Close
$39.22
Day's Range
38.25–40.35
52-Week Range
33.40–109.00
Volume
619.42K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.27
Valuation
Market Cap
$1.31B
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
23.94
EPS (ttm)Profit attributable to each share over the last twelve months.
−18.96
Financials (FY)
Revenue (FY)
$55.23M−43.89%
Net Income (FY)
−$164.08M
Profit marginThe share of revenue left as profit after all costs and taxes.
−287.84%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.14M
1-Year Return
−35.55%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.11M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NKTR closed at $38.27, −35.55% over 1 year.

Nektar Therapeutics (NKTR) has a market capitalization of $1.31B.

In fiscal 2025, NKTR reported revenue of $55.23M.

NKTR Stock Return by Calendar Year

Nektar Therapeutics (NKTR) 10-year return: what $10,000 became

1 year
$10,000 $6,445
−35.55%
5 years
$10,000 $1,541
−84.59%
10 years
$10,000 $1,913
−80.87%

If you had invested $10,000 in Nektar Therapeutics (NKTR) 10 years ago, at the close on October 21, 2016, it would have been worth $1,913 at the close on October 21, 2026: −80.87% in total, −15.25% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−9.48%
2025+203.08%
2024+66.07%
2023−75.22%
2022−83.27%
2021−20.53%
2020−21.26%
2019−34.32%
2018−44.96%
2017+386.72%
2016 (partial year)−28.91%

As of October 21, 2026.

NKTR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$55.23M−$164.08M−297.1%
2024$98.43M−$118.96M−120.9%
2023$90.12M−$276.06M−306.3%
2022$92.06M−$368.20M−400.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$55.23M$55.23M−$130.77M−$164.08M−297.1%
2024$98.43M$67.74M−$129.92M−$118.96M−120.9%
2023$90.12M$56.35M−$135.23M−$276.06M−306.3%
2022$92.06M$70.42M−$240.24M−$368.20M−400.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NKTR Valuation vs Biotechnology Median

Median of 608 stocks
MetricNKTRBiotechnology medianvs median
P/S ratio23.9413.3080% above
Profit margin−287.84%−38.31%249.5 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Nektar Therapeutics (NKTR) at $1.31B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 63 employees.

The most recent close on file for NKTR is $38.27, dated October 21, 2026. That is −$0.95 (−2.42%) against the previous close. Over the past 52 weeks the price has ranged from $33.40 to $109.00. The latest close sits 14.58% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $55.23M. Against the prior fiscal year total of $98.43M, that is a change of −43.89%. The same year closed with a net loss of $164.08M. The reported profit margin is −287.84%. That is 249.5 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −18.96.

Across the 4 fiscal years on file, revenue moves from $92.06M in 2022 to $55.23M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.31. Measured against sales, the shares trade at 23.94 times revenue. On price-to-sales that is 79.99% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.27. Annualized volatility over the trailing 10 years is 97.72%. Over the trailing twelve months the total return is −35.55%. Across 10 years the annualized return works out at −15.25%.

Growth & Income

No dividend is on file for NKTR.

So far in 2026 the total return is −9.48%. Across the complete calendar years on file, 2017 returned +386.72% and 2022 returned −83.27%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Nektar Therapeutics (NKTR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nektar Therapeutics NKTR $1.31B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Nektar Therapeutics has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Visit website →